Normethandrone

Overview

Normethandrone, also known as methylestrenolone or methylnortestosterone and sold under the brand name Metalutin among others, is a progestin and androgen/anabolic steroid (AAS) medication which is used in combination with an estrogen in the treatment of amenorrhea and menopausal symptoms in women. It is taken by mouth.[1–5] WP

Side effects of normethandrone include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire. It can also cause liver damage. Normethandrone is a progestin, or a synthetic progestogen, and hence is an agonist of the progesterone receptor, the biological target of progestogens like progesterone. It is also a synthetic AAS and hence is an agonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone (DHT). It has some estrogenic activity as well and no other important hormonal activity.[1][3–9] WP

Normethandrone was introduced for medical use by 1957. It is available only in a few countries, including Brazil, Indonesia, and Venezuela, and is available only in combination with methylestradiol or estradiol valerate.[1][2][10] WP

Uses, dosage and effects

Medical uses

Normethandrone is used in combination with an estrogen, either methylestradiol or estradiol valerate, in the treatment of amenorrhea and menopausal symptoms in women. It has also been used to treat dysmenorrhea in women. Normethandrone has been used successfully to inhibit libido in men with sexual deviance. Although normethandrone can be classified as an AAS and has strong such effects at sufficiently high doses, it is not typically used as such and is instead used medically only as a progestin. This is because it is so highly progestogenic in comparison.[1–4][11][12][13] WP

Available forms

Normethandrone is marketed in combination with methylestradiol in the form of oral tablets containing 5 mg normethandrone and 0.3 mg methylestradiol.[11][14] WP

Risks and side effects

Side effects

Normethandrone has been associated with symptoms of masculinization and hepatotoxicity.[6][7][15] WP

Pharmacology

Pharmacodynamics

Normethandrone shows high progestogenic activity. With sublingual administration in women, it has at least 150 times the potency of sublingual progesterone and 50 times the potency of sublingual ethisterone. It also has 10 times the potency of injected progesterone via this route. The oral potency of normethandrone in terms of endometrial transformation is similar to that of norethisterone. It has been reported to inhibit ovulation in women.[5][16][17][18] WP

In addition to its progestogenic activity, normethandrone has anabolic and androgenic activity and can produce effects associated with this activity. It has a high ratio of anabolic to androgenic activity. The anabolic potency of normethandrone is similar to that of norethandrolone and is much greater than that of nandrolone or metandienone. It is also greater than that of ethylestrenol. Normethandrone has been found to increase nitrogen retention, a measure of anabolic effect, at a dosage of 30 mg/day. Analogously to nandrolone and norethandrolone, 5α-dihydronormethandrone, the 5α-reduced metabolite of normethandrone, shows reduced affinity for the androgen receptor relative to normethandrone. Its affinity for the androgen receptor is specifically about 33 to 60% of that of normethandrone.[1][4][8][19–22] WP

Normethandrone has estrogenic activity via aromatization into methylestradiol.[3] WP

Pharmacokinetics

Normethandrone is metabolized by aromatase into methylestradiol in small quantities, similarly to methyltestosterone and metandienone. The metabolites of normethandrone have not been well-studied, but 5α-dihydronormethandrone is a likely metabolite formed by 5α-reductase.[3][23–26] WP

The pharmacokinetics of normethandrone have been reviewed.[27] WP

History

History

Normethandrone has been marketed for medical use since 1957. The combination of normethandrone and methylestradiol was introduced by at least 1966.[10][14] WP

Legal status

Generic names

Normethandrone has not been assigned an INN (International Nonproprietary Name) or other formal name designations. It is also known as methylestrenolone, methylnortestosterone, normethandrolone, and normethisterone.[2][28][29] WP

Brand names

Brand names of normethandrone include Batynid, Ginecosid, Ginecoside, Gynomin, Lutenin, Matronal, Mediol, Metalutin, Methalutin, Orgasteron, Orosteron, and Renodiol.[1][2][11][28][29][30] WP

Availability

Normethandrone is marketed in Brazil, Indonesia, and Venezuela in combination with methylestradiol or estradiol valerate.[1][2] WP

Chemistry

Formula

C19H28O2 PC

CAS number

514-61-4 PC

Molar mass (g/mol)

288.4 PC

IUPAC name (computed by PubChem)

(8R,9S,10R,13S,14S,17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one PC

SMILES

C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CCC4=CC(=O)CC[C@H]34 PC

InChIKey

ZXSWTMLNIIZPET-ZOFHRBRSSA-N PC

PubChem CID

5284597

IUPAC name

(8R,9S,10R,13S,14S,17S)-17-hydroxy-13,17-dimethyl-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one WP

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other Digital Medicines Information Suite | MedicinesComplete
2. Other Gynomin
3. Journal / agency Friedl KE. Reappraisal of the health risks associated with the use of high doses of oral and injectable androgenic steroids. NIDA Research Monograph. 1990. PMID 1964199
4. Other Krüskemper HL. Anabolic Steroids. 22 October 2013
5. Journal / agency Ferin J. A new substance with progestational activity; comparative assays in ovariectomized women; clinical results. Acta Endocrinologica. August 1956. doi:10.1530/acta.0.0220303 · PMID 13354223
6. Journal / agency Lundberg PO. Migraine Prophylaxis with Progestogens. European Journal of Endocrinology. 1962. doi:10.1530/acta.0.040S0005
7. Journal / agency Delorimier AA, Gordan GS, Lowe RC, Carbone JV. Methyltestosterone, Related Steroids, and Liver Function. Archives of Internal Medicine. August 1965. doi:10.1001/archinte.1965.03870020129023 · PMID 14315662
8. Journal / agency Brueggemeier RW. Encyclopedia of Molecular Cell Biology and Molecular Medicine. 2006. doi:10.1002/3527600906.mcb.200500066
9. Other Heftmann E. Steroid Biochemistry. 1970
10. Other Official Gazette of the United States Patent Office. 1957
11. Other Unlisted Drugs. 1982
12. Journal / agency Begni-Calvet D. Two properties of methylestrenolone (17-alpha-methyl-19-nortestosterone): its effectiveness in the treatment of dysmenorrhea, its anabolic action. Gynécologie Pratique. 1959. PMID 13798272
13. Journal / agency Servais J. A clinical study of cases of psychosexual disturbances in men treated by a libido inhibitor: Methylestrenolone. Archives of Sexual Behavior. 1973. doi:10.1007/BF01541012
14. Journal / agency Akingba JB, Ayodeji EA. Amenorrhea as a leading symptom of choriocarcinoma. The Journal of Obstetrics and Gynaecology of the British Commonwealth. February 1966. doi:10.1111/j.1471-0528.1966.tb05137.x · PMID 5948541
15. Journal / agency Feldman EB, Carter AC. Endocrinologic and metabolic effects of 17 alpha-methyl-19-nortestosterone in women. The Journal of Clinical Endocrinology and Metabolism. June 1960. doi:10.1210/jcem-20-6-842 · PMID 13822027
16. Journal / agency Horský J, Presl J. Ovarian Function and its Disorders: Diagnosis and Therapy. 1981. doi:10.1007/978-94-009-8195-9_11
17. Journal / agency Boschann HW. Observations of the role of progestational agents in human gynecologic disorders and pregnancy complications. Annals of the New York Academy of Sciences. July 1958. doi:10.1111/j.1749-6632.1958.tb54649.x · PMID 13583829
18. Journal / agency Camerino B, Sala G. Fortschritte der Arzneimittelforschung / Progress in Drug Research / Progrès des recherches pharmaceutiques. 1960. doi:10.1007/978-3-0348-7038-2_2 · PMID 14448579
19. Other Kochakian CD. Anabolic-Androgenic Steroids. 6 December 2012
20. Other Dorfman RI. Steroidal Activity in Experimental Animals and Man. 5 December 2016
21. Journal / agency Ojasoo T, Delettré J, Mornon JP, Turpin-VanDycke C, Raynaud JP. Towards the mapping of the progesterone and androgen receptors. Journal of Steroid Biochemistry. 1987. doi:10.1016/0022-4731(87)90317-7 · PMID 3695484
22. Journal / agency Behre HM, Kliesch S, Lemcke B, von Eckardstein S, Nieschlag E. Suppression of spermatogenesis to azoospermia by combined administration of GnRH antagonist and 19-nortestosterone cannot be maintained by this non-aromatizable androgen alone. Human Reproduction. December 2001. doi:10.1093/humrep/16.12.2570 · PMID 11726576
23. Other Thieme D, Hemmersbach P. Doping in Sports. 18 December 2009
24. Other Llewellyn W. Anabolics. 2011
25. Journal / agency Fragkaki AG, Angelis YS, Tsantili-Kakoulidou A, Koupparis M, Georgakopoulos C. Schemes of metabolic patterns of anabolic androgenic steroids for the estimation of metabolites of designer steroids in human urine. The Journal of Steroid Biochemistry and Molecular Biology. May 2009. doi:10.1016/j.jsbmb.2009.02.016 · PMID 19429460
26. Other Schjølberg TH. In Vitro Synthesis of Metabolites of three Anabolic Androgenic Steroids, by Human Liver Microsomes. 2013
27. Other Die Gestagene. 27 November 2013
28. Other Elks J. The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014
29. Other Morton IK, Hall JM. Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012
30. Other Negwer M, Scharnow HG. Organic-chemical drugs and their synonyms: (an international survey). 2001

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.